Interpace Diagnostics Receives Approval to Launch Thyroid Test in New York

Interpace Diagnostics announced today that it has received approval from New York State to launch its ThyraMIR diagnostic assay on formalin-fixed, paraffin-embedded tissue samples from thyroid nodules.

According to Interpace, its ThyraMIR assay is now the only molecular test approved to be used on indeterminate thyroid nodule samples presented through fine needle aspirates in Asuragen’s RNARetain cellular preservation device, cytology slides, and FFPE fixation in the State of New York.

Source: https://www.genomeweb.com/molecular-diagnostics/interpace-diagnostics-receives-approval-launch-thyroid-test-new-york